Clinical trial
Leveraging the Therapeutic Benefits of Transcranial Direct Current Stimulation to Treat Chemotherapy-related Chronic Pain and Psycho-cognitive Comorbidities in Cancer Survivors
NCT07912775 is registered in ClinicalTrials.gov with Instituto de investigación e innovación biomédica de Cádiz as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Leveraging the Therapeutic Benefits of Transcranial Direct Current Stimulation to Treat Chemotherapy-related Chronic Pain and Psycho-cognitive Comorbidities in Cancer Survivors
- Lead sponsor
- Instituto de investigación e innovación biomédica de Cádiz
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- November 30, 2028
- Enrollment
- 60 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
anxiety, cancer survivors, chemotherapy-related chronic pain, chronic pain, cognitive dysfunction, depression, neuropathic pain
Arms
As registered; 2 arms.
-
Active tDCS
Phase I (acute, double-blind): 5 consecutive daily sessions of active tDCS (2 mA, 20 minutes, 30-second ramp-up and ramp-down) combined with the Sternberg working-memory task (10 minutes at rest, then 10 minutes performing the task). Responders (at least 2-point reduction on the pain VAS from baseline) continue to Phase III (maintenance, open-label): active tDCS with the same scheme twice a week for up to 2 months.
-
Sham tDCS
Phase I (acute, double-blind): 5 consecutive daily sessions of sham tDCS (brief ramp-up and ramp-down at the beginning and end of the session, without sustained stimulation) combined with the Sternberg working-memory task (10 minutes at rest, then 10 minutes performing the task). Non-responders then receive Phase II (open-label crossover): 5 consecutive daily sessions of active tDCS. Responders, after Phase I or Phase II, continue to Phase III (maintenance, open-label): active tDCS twice a week for up to 2 months.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change in pain intensity (Visual Analogue Scale, VAS) after the acute phase
Change from baseline in pain intensity measured with the Visual Analogue Scale (VAS), comparing active tDCS with sham tDCS. Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate a worse outcome. Responders are defined as participants with a reduction of at least 2 points from baseline.
Lead sponsor's other trials
Instituto de investigación e innovación biomédica de Cádiz, most recent start first.
+1 more trial
Similar trials
Same condition (Neuralgia) and phase, most recent start first.
+377 more trials See the condition page